Psychedelic medicine: where things stand

Psychedelic medicine is moving fast. This page tracks what is approved, what is close, and what is still in research, so you can see clearly what we offer now and what is coming. Last updated October 2026.

Close to approval

• LSD for anxiety and depression. A pharmaceutical form of LSD called DT120 now has three positive phase 3 trials: Emerge in major depression (June 2026), and Voyage (August 2026) and Panorama (September 2026) in generalized anxiety disorder. In the anxiety trials, a single supervised dose improved anxiety scores significantly more than placebo at 12 weeks, with improvement seen as early as day two. The FDA has granted it Breakthrough Therapy designation for both anxiety and depression. The company plans to meet with the FDA late in 2026 and to file for approval in the first half of 2027. If approved, it would be given as a single measured dose in a supervised clinical setting, not as a daily medicine.

If you are considering a ceremony or retreat

Many people are now seeking psychedelic experiences outside of medicine, in retreats, ceremonies and other countries. How you prepare, who you are with and how you integrate afterward shape the experience as much as the substance. I do not provide or source psychedelics. I can help you look at the medical side first:

• Medication interactions. MAOIs, lithium, some antidepressants and some ADHD medicines can interact dangerously with psychedelics. Stopping an antidepressant to make room for one carries its own risks and needs a plan.
• Heart screening. Ibogaine in particular can cause dangerous heart rhythm problems and needs a careful cardiac evaluation before anyone considers it.
• Mental health history. A personal or family history of bipolar disorder or psychosis changes the risk, and is worth talking through honestly.
• Integration. Support afterward, to bring what you learned back into your body, your relationships and your daily life.

These conversations start with a 15-minute visit.